Payment overview · 2025
General Payments
$1,481.30
81 reported records · 24 companies
Healthcare provider profile · identity verified
Patrick M. Gray, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINDBER, PA · NPI 1427040088
Verified facts
What the public records show
CMS Open Payments records show Patrick M. Gray, MD received $1,481.30 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1866 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1866 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $260.66 | 17.6% | 17 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $196.60 | 13.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $155.61 | 10.5% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $112.46 | 7.6% | 5 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $67.49 | 4.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.72 | 4.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.07 | 4.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.38 | 4.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.47 | 3.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.10 | 3.2% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.61 | 3.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.70 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.02 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.54 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.78 | 2.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.49 | 2.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.41 | 2.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.46 | 2.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.49 | 1.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.08 | 1.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.35 | 1.2% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $17.14 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.13 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.54 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,481.30 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $167.14 | 15 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $164.56 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.91 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $135.07 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $112.46 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.81 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $89.74 | 5 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $67.49 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $67.49 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $59.38 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.10 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $45.61 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.17 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.04 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1866 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 346 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 209 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
153 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
197 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 54 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1866 | 211 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
155 | 152 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
130 | 92 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
209 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
147 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1866 | 211 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2439 | 395 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1990 | 256 |
| Eliquis | Apixaban | 1866 | 211 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1841 | 328 |
| Furosemide | Furosemide | 1623 | 264 |
| Amlodipine Besylate | Amlodipine Besylate | 1495 | 262 |
| Lisinopril | Lisinopril | 1462 | 263 |
| Potassium Chloride | Potassium Chloride | 1300 | 215 |
| Gabapentin | Gabapentin | 1035 | 161 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1027 | 177 |
| Metformin Hcl | Metformin Hcl | 889 | 157 |
| Sertraline Hcl | Sertraline Hcl | 888 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 843 | 159 |
| Trazodone Hcl | Trazodone Hcl | 834 | 113 |
| Donepezil Hcl | Donepezil Hcl | 770 | 103 |
| Clopidogrel | Clopidogrel Bisulfate | 662 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 658 | 120 |
| Losartan Potassium | Losartan Potassium | 600 | 139 |
| Simvastatin | Simvastatin | 579 | 104 |
| Omeprazole | Omeprazole | 571 | 104 |
| Mirtazapine | Mirtazapine | 564 | 87 |
| Famotidine | Famotidine | 558 | 89 |
| Citalopram Hbr | Citalopram Hydrobromide | 546 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 543 | 113 |
| Xarelto | Rivaroxaban | 520 | 48 |
| Montelukast Sodium | Montelukast Sodium | 506 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 493 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 476 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 460 | 77 |
| Buspirone Hcl | Buspirone Hcl | 426 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 414 | 82 |
| Memantine Hcl | Memantine Hcl | 402 | 63 |
| Allopurinol | Allopurinol | 397 | 75 |
| Lorazepam | Lorazepam | 386 | 100 |
| Levetiracetam | Levetiracetam | 351 | 44 |
| Carvedilol | Carvedilol | 348 | 61 |
| Jardiance | Empagliflozin | 346 | 54 |
| Tramadol Hcl | Tramadol Hcl | 341 | 103 |
| Azithromycin | Azithromycin | 330 | 250 |
| Quetiapine Fumarate | Quetiapine Fumarate | 318 | 41 |
| Alprazolam | Alprazolam | 301 | 76 |
| Glipizide Er | Glipizide | 298 | 62 |
| Bumetanide | Bumetanide | 293 | 45 |
| Myrbetriq | Mirabegron | 280 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 271 | 41 |
| Meloxicam | Meloxicam | 269 | 67 |
| Risperidone | Risperidone | 267 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 261 | 132 |
| Finasteride | Finasteride | 257 | 38 |
| Spironolactone | Spironolactone | 250 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 242 | 68 |
| Prednisone | Prednisone | 240 | 130 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 231 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 227 | 151 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 225 | 80 |
| Latanoprost | Latanoprost | 210 | 31 |
| Olanzapine | Olanzapine | 210 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 209 | 37 |
| Methylprednisolone | Methylprednisolone | 208 | 164 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 56 |
| Synthroid | Levothyroxine Sodium | 197 | 37 |
| Alendronate Sodium | Alendronate Sodium | 196 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 194 | 32 |
| Glipizide | Glipizide | 185 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 182 | 25 |
| Digoxin | Digoxin | 180 | 29 |
| Atenolol | Atenolol | 179 | 36 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 176 | 131 |
| Divalproex Sodium | Divalproex Sodium | 173 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 31 |
| Entresto | Sacubitril/Valsartan | 169 | 21 |
| Tradjenta | Linagliptin | 166 | 19 |
| Ozempic | Semaglutide | 160 | 35 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 155 | 152 |
| Linzess | Linaclotide | 153 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 152 | 81 |
| Trulicity | Dulaglutide | 147 | 18 |
| Ezetimibe | Ezetimibe | 136 | 29 |
| Methenamine Hippurate | Methenamine Hippurate | 135 | 22 |
| Celecoxib | Celecoxib | 133 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 130 | 92 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 25 |
| Midodrine Hcl | Midodrine Hcl | 127 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 126 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 34 |
| Nystatin | Nystatin | 121 | 60 |
| Sucralfate | Sucralfate | 121 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 35 |
| Cephalexin | Cephalexin | 119 | 81 |
| Pregabalin | Pregabalin | 118 | 20 |
| Propranolol Hcl | Propranolol Hcl | 117 | 17 |
| Bupropion Xl | Bupropion Hcl | 113 | 20 |
| Telmisartan | Telmisartan | 113 | 23 |
| Baclofen | Baclofen | 112 | 25 |
| Lactulose | Lactulose | 110 | 20 |
| Levofloxacin | Levofloxacin | 110 | 86 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 23 |
| Metformin Hcl Er | Metformin Hcl | 103 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 101 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 100 | 42 |
| Aripiprazole | Aripiprazole | 100 | 14 |
| Warfarin Sodium | Warfarin Sodium | 99 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 16 |
| Januvia | Sitagliptin Phosphate | 97 | 13 |
| Meclizine Hcl | Meclizine Hcl | 97 | 32 |
| Amantadine | Amantadine Hcl | 91 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 19 |
| Acetazolamide | Acetazolamide | 90 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 90 | 21 |
| Loperamide | Loperamide Hcl | 90 | 45 |
| Humalog Kwikpen U-100 | Insulin Lispro | 89 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 88 | 20 |
| Glimepiride | Glimepiride | 85 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 85 | 51 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 84 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 83 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 16 |
| Topiramate | Topiramate | 80 | 14 |
| Clonazepam | Clonazepam | 79 | 27 |
| Ibuprofen | Ibuprofen | 78 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 78 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 77 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 76 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 19 |
| Valsartan | Valsartan | 75 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 16 |
| Doxepin Hcl | Doxepin Hcl | 74 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 71 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 27 |
| Lamotrigine | Lamotrigine | 70 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 69 | 50 |
| Farxiga | Dapagliflozin Propanediol | 69 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 63 | 28 |
| Haloperidol | Haloperidol | 63 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 20 |
| Lacosamide | Lacosamide | 62 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 15 |
| Methotrexate | Methotrexate Sodium | 58 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Lansoprazole | Lansoprazole | 56 | 12 |
| Lovastatin | Lovastatin | 56 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 40 |
| Metolazone | Metolazone | 55 | 16 |
| Amoxicillin | Amoxicillin | 54 | 40 |
| Nifedipine Er | Nifedipine | 53 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 12 |
| Primidone | Primidone | 52 | 13 |
| Hydrocortisone | Hydrocortisone | 51 | 15 |
| Irbesartan | Irbesartan | 51 | suppressed |
| Mirabegron Er | Mirabegron | 51 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 50 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 50 | suppressed |
| Calcitriol | Calcitriol | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 49 | suppressed |
| Fluconazole | Fluconazole | 49 | 41 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 49 | 12 |
| Terazosin Hcl | Terazosin Hcl | 49 | suppressed |
| Mupirocin | Mupirocin | 47 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 17 |
| Dutasteride | Dutasteride | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Ssd | Silver Sulfadiazine | 45 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 45 | suppressed |
| Verapamil Er | Verapamil Hcl | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 41 | suppressed |
| Anastrozole | Anastrozole | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Phenobarbital | Phenobarbital | 39 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Clonidine | Clonidine | 37 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 37 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | 24 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Acetic Acid | Acetic Acid | 33 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 26 |
| Sulfasalazine | Sulfasalazine | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Clotrimazole | Clotrimazole | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 15 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 31 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 30 | 11 |
| Erythromycin | Erythromycin Base | 30 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 30 | 23 |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 13 |
| Theophylline Er | Theophylline Anhydrous | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 28 |
| Cyclosporine | Cyclosporine | 29 | suppressed |
| Hydroxyurea | Hydroxyurea | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 24 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | 19 |
| Dantrolene Sodium | Dantrolene Sodium | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Ibu | Ibuprofen | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Zonisamide | Zonisamide | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 13 |
| Nystop | Nystatin | 24 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | suppressed |
| Lumigan | Bimatoprost | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | 15 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 13 |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Lanoxin | Digoxin | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Risperidone Odt | Risperidone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | 11 |
| Rayos | Prednisone | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,481.30 · 81 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Flexitouch Plus, IBSRELA, INGREZZA, JARDIANCE, KRYSTEXXA, MOUNJARO, NURTEC ODT, Nimbl, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VERQUVO, VOQUEZNA, VOWST, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error